Quantitative and Engineered Elimination of Neosubstrates — AI/ML-enabled, target-centric molecular glue degrader discovery engine combining geometric deep learning for protein surface characterization, high-throughput screening, structural biology, and proprietary MGD library of 75,000+ compounds. Focused on immunology, inflammation, cardiovascular, oncology, and CNS diseases.

Roche Collaboration Platform · Roche

Strategic collaboration with Roche to identify and develop MGDs against cancer and neurological disease targets using Monte Rosa's QuEEN discovery platform. Monte Rosa leads preclinical discovery; Roche gains exclusive rights for further development upon defined handoff criteria.

Novartis I&I Collaboration Platform · Novartis

Collaboration, option, and license agreement with Novartis for discovery and development of degraders targeting immunology and inflammation programs. Monte Rosa applies QuEEN engine for one licensed I&I program and two optioned preclinical I&I programs; Novartis responsible for development and commercialization.

Biotech Distilled coverage (1)

2026-04-14 Monte Rosa Therapeutics (GLUE) - Scientific Deep Dive for MRT-2359, MRT-8102, and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.